These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 16813881

  • 1. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.
    J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Aug; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
    Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J.
    Urol Int; 2013 Aug; 90(1):41-4. PubMed ID: 23235105
    [Abstract] [Full Text] [Related]

  • 4. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 5. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H, Klotz L.
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [Abstract] [Full Text] [Related]

  • 6. [Total androgen blockade].
    Namiki M, Mizokami A.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract] [Full Text] [Related]

  • 7. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

  • 12. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
    Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS.
    J Clin Oncol; 2004 Jul 01; 22(13):2546-53. PubMed ID: 15226323
    [Abstract] [Full Text] [Related]

  • 13. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 14. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
    Salvador C, Planas J, Raventós C, Ropero J, Placer J, López MA, Morote J.
    Actas Urol Esp; 2012 Apr 01; 36(4):205-9. PubMed ID: 22178349
    [Abstract] [Full Text] [Related]

  • 15. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
    Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB, Abarelix Study Group.
    J Urol; 2002 Apr 01; 167(4):1670-4. PubMed ID: 11912385
    [Abstract] [Full Text] [Related]

  • 16. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
    Salman H, Bergman M, Blumberger N, Djaldetti M, Bessler H.
    Biomed Pharmacother; 2014 Feb 01; 68(1):21-4. PubMed ID: 24406295
    [Abstract] [Full Text] [Related]

  • 17. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H, Sakai I, Inoue TA, Hara I, Fujisawa M.
    Urol Int; 2006 Feb 01; 77(2):122-6. PubMed ID: 16888415
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
    Smith MR, Fallon MA, Goode MJ.
    Urology; 2003 Jan 01; 61(1):127-31. PubMed ID: 12559282
    [Abstract] [Full Text] [Related]

  • 20. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.
    Hinyokika Kiyo; 2001 Aug 01; 47(8):553-5. PubMed ID: 11579594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.